|
1
|
Cairns P: Renal cell carcinoma. Cancer
Biomarkers. 9:461–473. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Motzer RJ, Escudier B, Tomczak P, Hutson
TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J,
Hariharan S, et al: Axitinib versus sorafenib as second-line
treatment for advanced renal cell carcinoma: Overall survival
analysis and updated results from a randomised phase 3 trial.
Lancet Oncol. 14:552–562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tomita Y, Fukasawa S, Shinohara N,
Kitamura H, Oya M, Eto M, Tanabe K, Kimura G, Yonese J, Yao M, et
al: Nivolumab versus everolimus in advanced renal cell carcinoma:
Japanese subgroup analysis from the CheckMate 025 study. Jpn J Clin
Oncol. 47:639–646. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tanriverdi O: Review on targeted treatment
of patients with advanced-stage renal cell carcinoma: A medical
oncologist's perspective. Asian Pac J Cancer Prev. 14:609–617.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chow WH, Dong LM and Devesa SS:
Epidemiology and risk factors for kidney cancer. Nat Rev Urol.
7:245–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Perry JM, He XC, Sugimura R, Grindley JC,
Haug JS, Ding S and Li L: Cooperation between both
Wnt/{beta}-catenin and PTEN/PI3K/Akt signaling promotes primitive
hematopoietic stem cell self-renewal and expansion. Genes Dev.
25:1928–1942. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dasari VR, Kaur K, Velpula KK, Gujrati M,
Fassett D, Klopfenstein JD, Dinh DH and Rao JS: Upregulation of
PTEN in glioma cells by cord blood mesenchymal stem cells inhibits
migration via downregulation of the PI3K/Akt pathway. PLoS One.
5:e103502010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Carver BS, Chapinski C, Wongvipat J,
Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J,
Scher H, et al: Reciprocal feedback regulation of PI3K and androgen
receptor signaling in PTEN-deficient prostate cancer. Cancer Cell.
19:575–586. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Esteva FJ, Guo H, Zhang S, Santa-Maria C,
Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN and Yu D: PTEN,
PIK3CA, p-AKT, and p-p70S6K status: Association with trastuzumab
response and survival in patients with HER2-positive metastatic
breast cancer. Am J Pathol. 177:1647–1656. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li X, Yang Z, Song W, Zhou L, Li Q, Tao K,
Zhou J, Wang X, Zheng Z, You N, et al: Overexpression of Bmi-1
contributes to the invasion and metastasis of hepatocellular
carcinoma by increasing the expression of matrix metalloproteinase
(MMP)-2, MMP-9 and vascular endothelial growth factor via the
PTEN/PI3K/Akt pathway. Int J Oncol. 43:793–802. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brenner W, Färber G, Herget T, Lehr HA,
Hengstler JG and Thüroff JW: Loss of tumor suppressor protein PTEN
during renal carcinogenesis. Int J Cancer. 99:53–57. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hopkins BD, Fine B, Steinbach N, Dendy M,
Rapp Z, Shaw J, Pappas K, Yu JS, Hodakoski C, Mense S, et al: A
secreted PTEN phosphatase that enters cells to alter signaling and
survival. Science. 341:399–402. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hopkins BD, Hodakoski C, Barrows D, Mense
SM and Parsons RE: PTEN function: The long and the short of it.
Trends Biochem Sci. 39:183–190. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ahmed RA, Hopkins B, Palermo C, Sastra SA,
Rapp Z, Parsons R and Olive KP: Abstract A86: PTEN-Long and
gemcitabine combination treatment as a therapeutic for pancreatic
cancer. Cancer Res. 75 (13 Suppl):A862015. View Article : Google Scholar
|
|
16
|
Wang H, Zhang P, Lin C, Yu Q, Wu J, Wang
L, Cui Y, Wang K, Gao Z and Li H: Relevance and therapeutic
possibility of PTEN-long in renal cell carcinoma. PLoS One.
10:e1142502015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang R, Miner JJ, Gorman MJ, Rausch K,
Ramage H, White JP, Zuiani A, Zhang P, Fermandez E, Zhang Q, et al:
A CRISPR screen defines a signal peptide processing pathway
required by flaviviruses. Nature. 535:164–168. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou J, Wang C, Zhang K, Wang Y, Gong X,
Wang Y, Li S and Luo Y: Generation of human embryonic stem cell
line expressing zsGreen in cholinergic neurons using CRISPR/Cas9
system. Neurochem Res. 41:2065–2074. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yin H, Song CQ, Dorkin JR, Zhu LJ, Li Y,
Wu Q, Park A, Yang J, Suresh S, Bizhanova A, et al: Therapeutic
genome editing by combined viral and non-viral delivery of CRISPR
system components in vivo. Nat Biotechnol. 34:328–333. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zuckermann M, Kawauchi D and Gronych J:
Applications of the CRISPR/Cas9 system in murine cancer modeling.
Brief Funct Genomics. 16:25–33. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fresno Vara JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Luo J, Manning BD and Cantley LC:
Targeting the PI3K-Akt pathway in human cancer: Rationale and
promise. Cancer Cell. 4:257–262. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Carnero A and Paramio JM: The
PTEN/PI3K/AKT pathway in vivo, cancer mouse models. Front Oncol.
4:2522014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bassi C, Ho J, Srikumar T, Dowling RJ,
Gorrini C, Miller SJ, Mak TW, Neel BG, Raught B and Stambolic V:
Nuclear PTEN controls DNA repair and sensitivity to genotoxic
stress. Science. 341:395–399. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu Q, Li Z and Liu Q: Treatment with
PTEN-Long protein inhibits hepatitis C virus replication. Virology.
511:1–8. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pan MW and Hou LL: Relationship and tumor
inhibition between PTEN and PTEN-long. Sheng Li Ke Xue Jin Zhan.
47:355–360. 2016.(In Chinese). PubMed/NCBI
|
|
27
|
Krishnan SM, Sobey CG, Latz E, Mansell A
and Drummond GR: IL-1β and IL-18: Inflammatory markers or mediators
of hypertension? Br J Pharmacol. 171:5589–5602. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Daniele G, Guardado Mendoza R, Winnier D,
Fiorentino TV, Pengou Z, Cornell J, Andreozzi F, Jenkinson C,
Cersosimo E, Federici M, et al: The inflammatory status score
including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and
adiponectin underlies whole-body insulin resistance and
hyperglycemia in type 2 diabetes mellitus. Acta Diabetol.
51:123–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Faubel S, Lewis EC, Reznikov L, Ljubanovic
D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA and
Edelstein CL: Cisplatin-induced acute renal failure is associated
with an increase in the cytokines interleukin (IL)-1beta, IL-18,
IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp
Ther. 322:8–15. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ramesh G and Reeves WB: TNF-alpha mediates
chemokine and cytokine expression and renal injury in cisplatin
nephrotoxicity. J Clin Invest. 110:835–842. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Risdon RA, Sloper JC and De Wardener HE:
Relationship between renal function and histological changes found
in renal-biopsy specimens from patients with persistent glomerular
nephritis. Lancet. 2:363–366. 1968. View Article : Google Scholar : PubMed/NCBI
|
